Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype.

doi:10.1080/09553002.2021.1928786

Article

Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype.

International journal of radiation biology - 1 Jan 2021

Rossetti Alessandra, Petragnano Francesco, Milazzo Luisa, Vulcano Francesca, Macioce Giampiero, Codenotti Silvia, Cassandri Matteo, Pomella Silvia, Cicchetti Francesca, Fasciani Irene, Antinozzi Cristina, Di Luigi Luigi, Festuccia Claudio, De Felice Francesca, Vergine Massimo, Fanzani Alessandro, Rota Rossella, Maggio Roberto, Polimeni Antonella, Tombolini Vincenzo, Gravina Giovanni Luca, Marampon Francesco

Abstract excerpt

PURPOSE: Herein we describe the in vitro and in vivo activity of FK228 (Romidepsin), an inhibitor of class I HDACs, in counteracting and radiosensitizing embryonal (ERMS, fusion-negative) and alveolar (ARMS, fusion-positive) rhabdomyosarcoma (RMS). METHODS: RH30 (ARMS, fusion-positive) and RD (ERMS, fusion-negative) cell lines and human multipotent mesenchymal stromal cells (HMSC) were used. Flow cytometry...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor

Romidepsin (FK228) fails in counteracting the transformed phenotype of rhabdomyosarcoma cells but efficiently radiosensitizes, in vitro and in vivo, the alveolar phenotype subtype.

Abstract excerpt

Topics

Related research